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Abstract
The understanding of molecular mechanisms underlying diet and Alzheimer’s 
disease and the cholesterol connection are important for the prevention and 
treatment of Alzheimer’s disease linked to Type 3 diabetes and aberrant lipid 
metabolism. Cholesterol modulates amyloid beta generation with the ATP-binding 
cassette transporter 1 as a major regulator of cholesterol and phospholipids 
from cell membranes that are involved in amyloid beta transport from the brain 
to the liver for metabolism. In Parkinson’s disease, the α-synuclein protein binds 
to cholesterol (tilted peptide 67-78/isooctyl chain) in cell membranes. Fatty 
acids and phospholipids such as phosphatidylinositol in membranes sensitive 
to amyloid beta and α-synuclein binding/aggregation indicate the involvement of 
lipids in the progression of Alzheimer’s disease. Atherogenic diets with abnormal 
cell cholesterol homeostasis exist as a cellular mechanism, which is common 
to the aggregation of amyloid beta and α-synuclein proteins that induce both 
Alzheimer’s disease and Parkinson’s disease. Sirtuin 1,a nuclear receptor 
known to regulate cell functions by deacetylating both histone and non-histone 
targets when down regulated is associated with circadian abnormalities and 
with poor glucose and cholesterol metabolism linked to abnormal amyloid beta 
metabolism in Alzheimer’s disease and increased α-synuclein aggregation in 
Parkinson’s disease. The global obesity and Type 2 diabetes epidemic indicate 
that the down regulation of Sirtuin 1 with increased inflammatory processes and 
abnormal immune responses associated with increased plasma α-synuclein 
levels, has become important for the modulation of membrane ion channels 
and impairments in protein degradation with abnormal endoplasmic reticulum-
mitochondrial interactions associated with disturbed peripheral amyloid beta 
metabolism common to both Parkinson’s disease and Alzheimer’s disease.
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has become important for the possible prevention and treatment of 
AD and it is now linked to diabetes and poor cholesterol metabolism. 
Plasma cholesterol profiles such as elevated low density lipoprotein 
and decreased high density lipoprotein (HDL) levels have been 
associated with AD and are important risk factors for cardiovascular 
diseases. Furthermore, diets that are rich in fat and cholesterol have 
been associated with brain amyloidosis in rabbits and AD transgenic 
mice. Diabetes and dyslipidemia are linked to amyloidosis with 
relevance to calcium dyshomeostasis and neurodegenerative diseases 
[4]. Cholesterol modulates APP processing and Aβ generation with 
the action of 3 proteases [5-7]. Depletion of cholesterol and inhibition 
of intracellular transport of cholesterol or cholesterol esterification 
by drugs inhibited the production of Aβ formation in hippocampal 
neurons [8-13]. Studies indicate that cholesteryl ester (CE) levels are 
correlated with Aβ levels, and that cholesterol lowering drugs such 
as ACAT inhibitors directly modulate Aβ generation through the 
control of CE generation [14]. The ATP-binding cassette transporter 
1 (ABCA1) is a major regulator of HDL with the transport of 
cholesterol and phospholipids from cell membranes to HDL possibly 
plays a central role in cholesterol flux and Aβtransport from the CNS 
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Introduction
The main constituent of senile plaques, namely amyloid beta (Aβ) 
[1], is a proteolytic product of a larger protein, the amyloid precursor 
protein (APP). The main protein component of Alzheimer’s disease 
(AD) senile plaques, Aβ, was firstly purified and sequenced from 
cerebrovascular amyloid deposits which manifest as congophillic 
amyloid angiopathy [2]. Aβare found to be peptides of 39 to 43 amino 
acids in length, with an approximate molecular mass of 4.2 kDa [2]. 
Another study published from the same research group has linked 
Aβ to adult Down’s syndrome and AD [3]. The understanding of 
molecular mechanisms underlying the AD-cholesterol connection 
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to the periphery where it is transported to the liver for metabolism and 
subsequent excretion [15]. High fat and cholesterol diets may induce 
both AD and PD with the indications that abnormal cholesterol 
homeostasis exists as the cellular mechanisms that are common to 
the aggregation of Aβ and α-synuclein proteins [15-17].  In PD, the 
movement disorder is characterized by the aggregation of α-synuclein 
protein (14 kda) in Lewy body inclusions with dopaminergic neuron 
apoptosis in the substantia-nigra [18,19]. Epidemiological studies 
indicate that Type 2 diabetes and PD are closely linked with shared 
dysregulated pathways that involve molecular genetics, cell biology 
and insulin resistance in the pathogenesis of these diseases [20.21]. 
In Parkinson’s disease, the α-synuclein protein is an amyloidogenic 
protein and has been shown to bind to cholesterol (tilted peptide 67-
78) and α-synuclein has also been shown with binding to the isooctyl 
chain of cholesterol in membranes [22,23]. In recent publications, 
the binding of Aβ has been associated with cholesterol in membranes 
with the regulation of liver Aβ metabolism regulated by lipoprotein 
cholesterol levels [15]. The peripheral sink abeta hypothesis [16] is 
closely associated with cholesterol regulation and possibly connected 
to the metabolism of Aβ and α-synuclein proteins in diabetes, AD, PD 
and Huntington’s disease. In diabetes, circadian clock abnormalities 
[24] are central to disease progression and circadian disturbances are 
also found in neurodegenerative disease that involves AD and PD 
[25-28]. Regulation of the peripheral Aβ clearance is central to the 
disease of diabetes with circadian clock abnormalities now believed 
to be the origin of poor liver glucose, cholesterol and Aβ metabolism 
in diabetes [16]. Neurons in the hypothalamus are responsible for 
various connections to other brain regions and one of the important 
functions of the hypothalamus is control of the daily light dark 
cycle. The suprachiasmatic nucleus (SCN) may regulate the sleep-
wake cycle and peripheral oscillators with effects on anxiety, stress, 
depression and food intake. In response to the daily sleep/wake cycle 
Aβ metabolism, α-synuclein metabolism is controlled by the circadian 
rhythm, SCN [29-32] with relevance to food intake and release of 
pineal gland melatonin. Disturbances in the SCN will alter energy and 
liver glucose and Aβ metabolism with hyperglycemia closely involved 
with abnormal resetting of circadian rhythms and melatonin release.
Sirt 1 and insulin resistance involve circadian 
dysregulation with connections to membrane lipids and 
protein aggregation
Sirtuin 1 (Sirt1) is one of the nuclear receptors that is known to 
regulate several cell functions by deacetylating both histone and non-
histone targets [33]. Sirt1 is an NAD(+)dependent class III histone 
deacetylase protein that targets transcription factors to adapt gene 
expression to metabolic activity, insulin resistance and inflammation 
in chronic diseases [34-38]. Nutritional regulation (calorie restriction 
and high fat feeding) of Sirt1 that is involved in the hypothalamic 
and SCN control of food intake with regulation of the central 
melanocortin system via the fork head transcription factor has been 
reported [39-42]. Sirt1 dysregulation has been closely linked with 
alterations in appetite regulation and with circadian clock disorders 
that are associated with obesity and diabetes. In support of Sirt1’s 
role in circadian rhythms [43-47] subjects carrying minor alleles at 
Sirt1 and CLOCK loci, displayed a higher resistance to weight loss 
as compared with homozygotes for both major alleles, suggesting 
links between the circadian clock and Sirt1 function. Sirt1 is involved 
in neuron proliferation with effects on cellular cholesterol and lipid 
homeostasis by the regulation of liver X receptor (LXR) proteins. 
Sirt1 has been closely linked to Aβ metabolism in AD (Figure 1) and 
α-synuclein metabolism in PD with circadian dysregulation that is 
associated with protein aggregation [29-32] and with implications to 
Sirt1 research and therapeutics in Huntington’s disease [48].
Sirt1 is involved in the deacetylation and ubiquitination of LXR 
with regulation of the expression of LXR targets that are involved 
in cellular cholesterol metabolism such as ABCA1 (Figure 1) and 
SREBP-1c [49-51]. AMP-activated protein kinase (AMPK) activation 
by Sirt 1 may be involved in the LXR-SREBP-1c expression involved 
in glial-neuron interactions that are associated with the circadian 
cholesterol metabolism [52-55]. Sirt1 is involved with deacetylation 
of peroxisome-proliferator-activated receptor (PPAR) gamma 
co-activator 1 α (PGC-1 α) a co-activator of the LXR involved in 
mitochondrial biogenesis and fatty acid beta-oxidation [56-61]. LXR 
involved with cell cholesterol efflux has been shown to regulate the 
expression of α-synuclein and the secretion of cellular Aβ [62-64]. 
Interests in cholesterol regulation of α-synuclein has increased with 
regulation of α-synuclein expression by 27 OH cholesterol [65]. 
Circadian dysfunction has been found in mouse models of PD [66] 
and Sirt1dysregulation in diabetes involved with circadian rhythm 
[31] and membrane cholesterol dyshomeostasis may involve in 
α-synuclein aggregation and abnormal Aβ metabolism in neurons 
[4,67-72]. Molecular mechanisms involved with neuroendocrine 
diseases such as obesity and diabetes are closely related to insulin 
resistance and require attention since metabolic dysfunction has also 
been associated with neurodegeneration [4,73]. The global increase in 
these chronic diseases supports a role for lipids such as cholesterol, 
sphingomyelin and its metabolites in the pathogenesis of these 
diseases. Lipidomics, as a tool for the development with diagnosis 
of abnormal lipid metabolism as an early lipid biomarker panel, has 
Figure 1: Sirt 1 effect on cell cholesterol efflux determines Aβ metabolism 
associated with α-synuclein aggregation. 1. Sirt1 an NAD(+) dependent 
class III histone deacetylase (nuclear receptor) is involved in neuronal 
proliferation. 2. Sirt1 has been closely linked to circadian clock disorders and 
to A metabolism in AD and α-synuclein metabolism in PD. 3. Sirt1 effects on 
cellular cholesterol is by regulation of PGC 1 alpha and LXR transcription 
factors. LXR targets ABCA1 and SREBP-1c that are intimately involved in 
glial-neuron interactions associated with cholesterol, α-synuclein and Aβ 
metabolism. 4. Downregulation of Sirt1 decreases Aβ metabolism associated 
with α-synuclein aggregation and mitochondrial apoptosis with ER stress in 
cells. N: Nucleus; Ca2+: Calcium; apo E: Apolipoprotein E.
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become important to diabetes, PD and AD since its comparison and 
inclusion with other biomarker panels will allow sensitive detection 
and early diagnosis of metabolic dysfunction and its relevance to AD 
[74]. Interests in proteins and their interactions with membrane lipids 
in neurodegenerative diseases have accelerated with the existence of Aβ 
and α-synuclein pathologies  in individuals with neurodegeneration 
[75]. In particular, α-synuclein has been linked to mitochondria and 
endoplasmic reticulum interactions with endoplasmic reticulum 
stress associated with calcium levels and α-synuclein aggregation [76-
79]. The role of diet on α-synuclein aggregation in the modulation 
of the Aβ cascade, has become important with Aβ oligomer or 
toxic fibril formation that is associated with membrane cholesterol, 
sphingomyelin, phospholipids and fatty acids (Figure 2). The role of 
cholesterol in membranes is essential for protein interactions and 
metabolism of lipoproteins [80] with the isooctyl chain in cholesterol 
essential as a regulator of lipid metabolism [80]. The binding of 
α-synuclein to the isooctyl chain of cholesterol in membranes allows 
regulation of peripheral cholesterol metabolism with relevance to 
α-synuclein biology and the peripheral sink abeta hypothesis [15,16].
Neurodegenerative diseases and abnormal protein and cholesterol 
interactions (isooctyl chain of cholesterol) and other membrane 
lipids may involve the consensus cholesterol-binding motifs CRAC, 
CARC or a tilted peptide [22,23]. α-synuclein has been shown to bind 
to specific sites on the cholesterol such as the tilted peptide [67-78] 
and with binding to the isooctyl chain of cholesterol. The formation 
of cholesterol-rich domains [81,82] in membranes may involve both 
α-synuclein and Aβ and the insertion of both proteins in membranes 
are influenced by the various fatty acids, glycosphinglipids, 
phospholipids (anionic lipids) and gangliosides that may determine 
Aβ oligomer formation and α-synuclein aggregation (Figure 2) in 
cells [83-92]. The oligomers that contain both Aβ and 
α-synuclein have recently been reported with indications that 
nutrition and dietary lipids such as phosphatidylinositol [15] may 
be important in the mechanistic links between Aβ accumulation and 
α-synuclein pathogenesis (Figure 2) [16]. Fatty acids such as butyric 
acid [93] have become important for nutrition and neurodegenerative 
diseases and the used phenyl butyric acid has been assessed for the 
reduction of Aβ plaques and increased α-synuclein content in the 
brains of transgenic mice [94,95]. Furthermore, the interactions 
between α-synuclein and Aβ (Figure 2) may corrupt apo E-Aβ 
interactions [15,96] or apo E-ABCA1 interactions [97] with relevance 
to α-synuclein’s role in brain amyloidosis and neurodegeneration 
[98-100]. Down regulation of Sirt1 affectsLXR-ABCA1 that regulates 
apo E-ABCA1 [97] interactions with effects on cholesterol efflux, 
α-synuclein aggregation and Aβ metabolism.
Cholesterol-ceramide connections provide links between 
diabetes, PD and AD
The global increase in chronic diseases such as obesity and diabetes 
supports a role for lipids such as ceramide and their metabolites in the 
pathogenesis of these diseases [74]. The link between the cholesterol-
ceramide connections to diabetes and AD [102-104] has indicated the 
role of ceramide in the pathogenesis of PD and AD that is also referred 
to as Type 3 diabetes [105]. The cholesterol-ceramide connection 
linked with aging, diabetes and AD, is associated with increased 
α-synuclein-Aβ interactions in membranes that are associated with 
conformational Aβ transitions to benign or toxic amyloid assembly 
states [106]. Aβ intermediates modulated by α-synuclein (Figure 2) 
possibly determine the role of calcium channels [4,77-79,107] with 
relevance to membrane biology and neurodegeneration. α-syunclein 
is found in peripheral tissues and plasma with release of the protein 
from the gastrointestinal tract, macrophages, glands and skin that 
has been measured [108-113]. Macrophages may overexpress 
α-synuclein [109,111,112] and implications for the rise in plasma 
α-synuclein in human plasma, are sensitive to beta-cell function 
and insulin secretion [114]. α-synuclein and its role in inflammatory 
responses is closely linked to obesity and diabetes [114] with the 
γ-synuclein [115] regulation of lipid and Aβ metabolism in adipose 
tissue controlled by Sirt1 [116]. Effects of lipopolysaccharide (LPS) on 
the induction of α-synuclein and ceramide synthesis in macrophages 
[117,118] and α-synuclein release from the intestine [119] increased 
the α-synuclein levels in human plasma. LPS has been shown to effect 
cholesterol efflux by the modulation of the LXR-ABCA1 [120,121] 
pathways via Sirt1/LXR-ABCA1 interactions and lowering LPS has 
become important to reduce metabolic diseases with LPS models now 
reported for PD [122,123]. LPS effects macrophage SREBP expression 
and inhibits liver PGC 1 α expression linked to abnormal Sirt1 cell 
regulation [124-126]. LPS mediated corruption of cholesterol efflux 
in macrophages that has been reported with the importance of 
cholesterol-rich lipoprotein interactions for the neutralization of 
LPS in metabolic diseases and diabetes [127-133]. Close connections 
between ceramide and LPS, have been reported in cells [134,135] with 
disturbed cellular cholesterol efflux in diabetes, AD and PD.
Diets with low calorie contents (high fibre), nutritional 
interventions, appropriate protein contents (low to moderate), 
xenobiotic free and activators of Sirt1 nuclear receptor and 
transcription factors [4,15,16,73] have been shown to improve 
the cell and lipoprotein metabolism of cholesterol and ceramide 
Figure 2: Membrane lipids determine and influence A oligomer formation and 
α-synuclein interactions with cell membranes. 1. Membranes with increased 
ceramide-cholesterol interactions and low PI promote Aβ oligomerization. 
2. Membrane lipids such as sulfatide (101) determine the aggregation of 
α-synuclein with effects on Aβ oligomerization. 3. Apo E-ABCA1 interactions 
determine membrane cholesterol contents and regulate interactions between 
α-synuclein and Aβ that are influenced by various fatty acids, gangliosides, 
sphingolipids, ceramide and phospholipids (anionic lipids). Mechanistic 
links to Aβ accumulation indicate the importance of oligomers that contain 
both Aβ and α-synuclein that develop with unhealthy diets that are low in 
phosphatidylinositol (PI) and butyric acid.
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[74] with implications for α-synuclein and abeta metabolism in 
obesity, diabetes and neurodegenerative diseases. Effects of exercise 
on ceramide metabolism have been measured with the increased 
ceramide or normal ceramide levels in the muscle and heart [136-
138]. Adiponectin has been shown to suppress α-synucleopathies 
in animal models with systemic effects of adiponectin on ceramide 
metabolism [139-141]. Nutritional interventions to increase plasma 
adiponectin levels require lifestyle and dietary changes to prevent 
stroke, PD and AD [142]. Increases in ceramide levels in cells displace 
cholesterol with effects on α-synuclein and Aβ interactions [143,144]. 
Polyanions and polycations have an important electrostatic role in 
α-synuclein aggregation with drugs such as suramin (polyanionic) 
that are used to inhibit LPS inflammatory effects and shown to 
increase ceramide levels [145-148] in cells with effects of suramin on 
Sirt1 inhibition [149]. Suraminhas been shown to bind to low density 
lipoproteins and to the low density lipoprotein receptor and to block 
LDL uptake [150,151]. Coumarins [152-154] and adiponectin [155-
156] have been used to inhibit LPS effects and modulate the activation 
of Sirt1 with therapeutic effects in the treatment of PD. LPS [157,158] 
and Sirt1 [159,160] are linked to food intake and appetite regulation. 
Nutritional diets that contain phytosterols and butyric acid may control 
glucose homeostasis and stabilize membrane cholesterol-ceramide 
interactions [107]. However, butyric acid effects on T cell apoptosis 
have been reported and induced by an increase in cellular ceramide 
[161,162]. High fibre diets that control membrane cholesterol and 
cellular ceramide contents [74,102-104] are particularly relevant to 
activate the liver and brain nuclear receptors and stabilize membrane 
α-synuclein and Aβ transport in neurodegenerative diseases.
Conclusion
In the current global obesity and diabetes epidemic chronic 
diseases such as NAFLD, cardiovascular disease, kidney disease 
and neurodegenerative diseases such as PD and AD have increased 
in the developing and developed world. Links between metabolic 
diseases and AD indicate that Type 3 diabetes is on the increase in 
various countries. The Type 2 diabetes epidemic is linked to PD and 
associated with the Type 3 diabetes in AD. Unhealthy nutrigenomic 
diets down-regulate brain and hepatic Sirt1 associated with insulin 
resistance, α-synuclein aggregation and Aβ dyshomeostasis in AD 
and PD. Nutritional diets that are low in calories activate the brain 
and liver Sirt1 activity and increase α-synuclein and Aβ metabolism. 
Specific dietary lipids requirements such as increased PI contents 
may act to stabilize membranes and favour lipid-protein interactions 
that promote the metabolism of α-synuclein and Aβ in various 
cells. The current global epidemic with the risk of accelerated brain 
disease such as stroke may involve peripheral organ diseases where 
abnormal cholesterol and ceramide interactions may determine toxic 
α-synuclein and Aβ assemblies that lead to early apoptosis and cell 
death in chronic diseases.
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